FASENRA? (benralizumab) is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

FASENRA? (benralizumab) for Severe Eosinophilic Asthma | For HCPs


Redirect me
Take me to your homepage

You are about to be redirected to another page. We are not responsible for the content of that page or the consequences it may have on you.